Core Viewpoint - Nykredit Realkredit A/S has received approval to redeem its SEK 1,000,000,000 Subordinated Floating Rate Notes on the first Optional Redemption Date, which is set for 31 March 2026, including accrued interest [1]. Group 1 - Nykredit Realkredit A/S has obtained approval from the Danish Financial Supervisory Authority for the redemption of its subordinated notes [1]. - The total amount of the subordinated notes to be redeemed is SEK 1,000,000,000 [1]. - The redemption will occur on 31 March 2026 at the Final Redemption Amount plus accrued interest [1].

Core Viewpoint - Cognition Therapeutics is advancing the development of zervimesine for treating dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of DLB patients, following positive feedback from the FDA [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related neurodegenerative disorders [8] - The company has completed Phase 2 studies of zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by significant grants from the National Institute on Aging [8] Drug Development - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases, including Alzheimer's and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [6][7] - The Phase 2 SHIMMER study demonstrated zervimesine's positive impact on neuropsychiatric symptoms, showing an 86% slowing of decline on the neuropsychiatric inventory compared to placebo [5] Regulatory Strategy - The company plans to pursue a registrational path for zervimesine based on the strength of Phase 2 data and FDA meeting minutes, aiming to expedite its market entry [2][3] - Cognition expects to meet with the FDA Division of Psychiatry to discuss the DLB psychosis program by mid-2026 [2] Patient Impact - DLB psychosis significantly burdens patients and caregivers, leading to higher healthcare costs and earlier institutionalization, with no approved medications currently available for this condition [4] - Zervimesine has shown a favorable impact on cognitive fluctuations, memory, movement, and daily living activities without impairing motor skills, addressing a critical need for DLB patients [3]

Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's product candidates, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved treatments currently available [6]. - The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, targets microcystic lymphatic malformations and other skin conditions, while QTORIN™ pitavastatin is aimed at treating disseminated superficial actinic porokeratosis [6].

Core Viewpoint - Alterity Therapeutics is advancing ATH434 in late-stage clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies [1][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [1][10] - The company is preparing to initiate a Phase 3 pivotal trial in MSA, having demonstrated clinically meaningful efficacy in a Phase 2 clinical trial [10] Disease Background - MSA is characterized by motor impairment, autonomic dysfunction, and rapid loss of independence, with symptoms resembling Parkinson's disease, making early diagnosis challenging [2][9] - The disease affects up to 50,000 individuals in the U.S., and there are currently no approved drugs to slow its progression or cure it [9] Clinical Development of ATH434 - ATH434 is an investigational oral therapy designed to redistribute excess iron in the brain, which contributes to neurodegeneration in MSA [3][6] - Positive results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial showed robust clinical efficacy and a favorable safety profile [6][8] - The Phase 2 trial enrolled 77 adults and demonstrated significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [8] Research and Biomarkers - The clinical program incorporates biomarkers and advanced neuroimaging to better characterize disease progression and assess therapeutic impact [4] - Biomarkers indicated that both dose levels of ATH434 reduced iron accumulation in MSA-affected brain regions and showed trends in preserving brain volume [8] Awareness and Advocacy - Throughout MSA Awareness Month, the company will share educational information and highlight the experiences of the MSA community, emphasizing the need for continued research [5]

Group 1 - Statkraft will disclose its fourth quarter results for 2025 and the annual report for 2025 on March 5, 2026, at 08:00 a.m. CET [1] - The materials related to the results will be available on Statkraft's website and the Oslo Stock Exchange's news service [1] - A webcast presentation of the results will take place at 09:30 a.m. CET, conducted in English [2] Group 2 - Investor contact for Statkraft is Arild Ratikainen, who can be reached via phone or email [3]

Group 1 - Fancamp Exploration Ltd. has received notice from The Canadian Chrome Company Inc. regarding the extension of the maturity date of a secured convertible promissory note from September 1, 2026, to August 31, 2027, contingent on no event of default occurring before September 1, 2026 [1] - The secured convertible promissory note, originally issued on September 1, 2022, has a principal amount of C$34.5 million, bearing an annual interest rate of 6%, and includes equity interests in CCC and a 2% net smelter return royalty on mining claims [2] - Fancamp is focused on mineral exploration and has a diversified portfolio that includes interests in copper, gold, zinc, titanium, chromium, iron, and rare-earth metals, with significant projects in Ontario, Québec, and New Brunswick [3] Group 2 - The corporation has monetization opportunities from its transaction with CCC in the Ring of Fire region, which is known for its high mineral potential [3] - Fancamp holds a 96% interest in Magpie Mines Inc., which owns one of the largest undeveloped hard rock titanium deposits globally, according to USGS data [3] - A strategic reorganization has led to the incorporation of a subsidiary, Goldera Exploration Ltd., aimed at spinning out core exploration projects to create two distinct entities for shareholders [3]

Core Viewpoint - Navigator Holdings Ltd. has secured a senior secured pre- and post-delivery term loan of up to $133.77 million to finance the construction of two new liquefied ethylene gas carriers, marking a significant step in its newbuilding program and fleet renewal efforts [1][2][4]. Financial Details - The loan will cover up to 65% of the pre-delivery and delivery instalments to Jiangnan Shipyard and China Shipbuilding Trading Co., Ltd. for the construction of the new vessels, with the remaining costs funded from the company's cash resources [2]. - The Facility Agreement has a post-delivery tenor of five years, secured by mortgages over the new vessels, with interest set at SOFR plus 1.50% [3]. Company Overview - Navigator Holdings Ltd. operates the world's largest fleet of handysize liquefied gas carriers, specializing in the transportation of petrochemical gases, including ethylene, ethane, liquefied petroleum gas (LPG), and ammonia [5]. - The company owns a 50% stake in an ethylene export marine terminal in Texas and has a fleet of 55 semi- or fully-refrigerated liquefied gas carriers, enhancing its role in the liquefied gas supply chain [5].

Core Viewpoint - HBT Financial, Inc. has successfully completed its merger with CNB Bank Shares, Inc., enhancing its market presence in central Illinois, Chicago MSA, and St. Louis MSA markets [2][3]. Company Overview - HBT Financial, Inc. is headquartered in Bloomington, Illinois, and serves as the holding company for Heartland Bank and Trust Company, with banking operations dating back to 1920. As of December 31, 2025, HBT Financial reported total assets of $5.1 billion, total loans of $3.5 billion, and total deposits of $4.4 billion [6]. Merger Details - The merger involved CNB merging with a wholly-owned subsidiary of HBT, with CNB becoming a wholly-owned subsidiary of HBT. Subsequently, CNB Bank merged into Heartland Bank, which continues as the surviving entity. As of December 31, 2025, CNB had total assets of $1.8 billion, total loans of $1.3 billion, and total deposits of $1.5 billion [1][2]. Leadership Changes - Following the merger, the Boards of HBT Financial and Heartland Bank expanded, appointing James T. Ashworth and Nancy L. Ruyle as new directors, effective March 1, 2026. Their initial term will expire at the HBT Financial 2026 Annual Meeting of Stockholders [3][4]. Strategic Fit - The merger is described as a strong cultural and strategic fit, aimed at enhancing the banking experience for customers. HBT Financial has a history of successful bank integrations and is focused on a smooth transition for CNB's customers, employees, and shareholders [3][4].

Core Insights - uniQure N.V. reported updated Phase I/II data for AMT-191 in Fabry disease, showing durable, dose-dependent increases in α-Gal A enzyme activity [1] - The company has a strong financial position with approximately $622.5 million in cash and equivalents as of December 31, 2025, expected to fund operations into the second half of 2029 [1][13] - The CEO expressed confidence in AMT-130 as a potential first disease-modifying therapy for Huntington's disease, despite not yet aligning with the FDA on an approval pathway [2] Financial Performance - Revenue for the year ended December 31, 2025, was $16.1 million, a decrease from $27.1 million in 2024, primarily due to a $10.7 million drop in collaboration revenue [14] - Research and development expenses were $140.7 million for 2025, down from $143.8 million in 2024, mainly due to reduced costs following the divestment of the Lexington facility [16] - The net loss for the year ending December 31, 2025, was $199.0 million, or $3.46 per share, compared to a net loss of $239.6 million, or $4.92 per share, in 2024 [21][22] Clinical Developments - AMT-130 for Huntington's disease showed a statistically significant 75% slowing in disease progression at 36 months compared to an external control [5] - The company completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 for refractory mesial temporal lobe epilepsy, with additional data expected in the first half of 2026 [4][11] - AMT-191 demonstrated dose-dependent elevations in α-Gal A activity, with six of 11 patients withdrawing from enzyme replacement therapy [11] Regulatory Engagement - The company held a Type A meeting with the FDA regarding AMT-130 and plans to request a follow-up Type B meeting in the second quarter of 2026 [4][6] - The FDA indicated that the data from Phase I/II studies compared to an external control may not be sufficient for a marketing application, recommending a prospective, randomized, double-blind study [6] Upcoming Events - uniQure will host an earnings call on March 2, 2026, to discuss its financial results and business updates [1][23] - The company is scheduled to participate in several investor conferences in March and April 2026 [26]

Core Viewpoint - Nykredit Realkredit A/S has received approval to redeem its EUR 500 million Additional Tier 1 Capital Notes, scheduled for redemption on April 15, 2026, at the Outstanding Principal Amount plus accrued interest [1]. Group 1 - Nykredit Realkredit A/S will redeem EUR 500,000,000 Perpetual Non-cumulative Resettable Additional Tier 1 Capital Notes [1]. - The redemption is in accordance with the terms outlined in the Offering Circular [1]. - The redemption date is set for the First Call Date on April 15, 2026 [1].